Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascular Aging
$6M early-stage biotech investment supplemented by $2.3M non-dilutive grant funding
ENCINITAS, Calif., Jan. 3, 2024 -- (Healthcare Sales & Marketing Network) -- Vasa Therapeutics, Inc. ("Vasa"), a preclinical stage biopharmaceutical company d... Biopharmaceuticals, Cardiology, Venture Capital Vasa Therapeutics, cardiac fibrosis, atrophy, heart failure
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cardiology | Cardiovascular | Funding | Grants | Heart | Heart Failure | Marketing | Pharmaceuticals | Venture Capital